Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Carvedilol: therapeutic application and practice guidelines

B E Bleske1, E M Gilbert, M A Munger

  • 1University of Michigan College of Pharmacy, Ann Arbor, USA.

Pharmacotherapy
|August 6, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient preferences for healthcare delivery through community pharmacy settings in the USA: A discrete choice study.

Journal of clinical pharmacy and therapeutics·2017
Same author

Adherence to controller asthma medications: 6-month prevalence across a US community pharmacy chain.

Journal of clinical pharmacy and therapeutics·2015
Same author

Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.

Journal of clinical pharmacy and therapeutics·2014
Same author

Immune function surveillance: association with rejection, infection and cardiac allograft vasculopathy.

Transplantation proceedings·2012
Same author

Noninvasive diagnosis of cardiac allograft rejection using echocardiography indices of systolic and diastolic function.

Transplantation proceedings·2011
Same author

Impact of donor left ventricular hypertrophy on survival after heart transplant.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same journal

Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

Response to Comment on "Pharmacokinetic Analysis of Intravenous Push Cefepime in Critically Ill Patients With Sepsis".

Pharmacotherapy·2026
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
See all related articles

Carvedilol, a beta-blocker, effectively reduces mortality and disease progression in heart failure patients when added to standard treatments. It is well-tolerated and improves quality of life, with clinical guidelines available for its use.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Heart failure progression is linked to neurohormonal activation and impaired myocardial energetics.
  • Therapies targeting these mechanisms offer significant benefits.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of carvedilol in heart failure management.
  • To provide clinical guidelines for carvedilol use.

Main Methods:

  • Carvedilol, a nonselective beta-adrenergic blocker with vasodilating properties, was administered to heart failure patients.
  • Outcomes assessed included mortality, disease progression, and quality of life.

Main Results:

  • Carvedilol addition to standard therapy significantly reduced mortality.
  • The drug slowed heart failure progression and improved patient quality of life.

Related Experiment Videos

  • Carvedilol was well-tolerated when administered per guidelines.

    • Conclusions:

    • Carvedilol is a beneficial therapy for heart failure, improving survival and quality of life.
    • Adherence to recommended guidelines ensures good tolerability.
    • Clinical guidelines are provided to support optimal use of carvedilol.